<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491334</url>
  </required_header>
  <id_info>
    <org_study_id>VTI-03</org_study_id>
    <secondary_id>1R43AG034714</secondary_id>
    <nct_id>NCT01491334</nct_id>
  </id_info>
  <brief_title>Validation of Transvaginal Tactile Imaging</brief_title>
  <acronym>VTI-03</acronym>
  <official_title>A Clinical Validation Study With Transvaginal Tactile Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Artann Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Artann Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate safety and effectiveness in assessment of the female&#xD;
      pelvic floor tissue, and, assess the ability of Vaginal Tactile Imager (VTI) to detect early&#xD;
      prolapse conditions and characterize the outcome of reconstructive surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. The device will detect significant differences in tissue elasticity and anatomy for&#xD;
           women with normal pelvic floor versus women with prolapse stage 1.&#xD;
&#xD;
        2. The device will detect significant differences in tissue elasticity and anatomy for&#xD;
           patients before and after reconstructive surgery.&#xD;
&#xD;
        3. The device will detect significant differences in tissue elasticity and anatomy among 3&#xD;
           groups of patients with prolapse stages 1, 2 and 3.&#xD;
&#xD;
        4. The device will detect significant differences in tissue elasticity among 3 control&#xD;
           groups with normal pelvic floor conditions (nulliparous women at age 21-30, parous women&#xD;
           at age 31-40, and postmenopausal women).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness in assessment of the pelvic floor tissue conditions.</measure>
    <time_frame>Two years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ability in early detection of prolapse conditions.</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ability in characterization of the outcome of pelvic floor reconstructive surgery.</measure>
    <time_frame>Two years.</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">158</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Asymptomatic</arm_group_label>
    <description>Asymptomatic women presenting at various ages without prolapse condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symptomatic</arm_group_label>
    <description>Symptomatic women presenting with prolapse conditions with no prior surgeries and women presenting with surgery scheduled with or without prior surgery.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The patient pool will comprise of 200 female patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is female of 21 years or older AND HAS AT LEAST ONE OF THE FOLLOWING&#xD;
&#xD;
          -  No evidence of pelvic organ prolapse and no prior pelvic surgery&#xD;
&#xD;
          -  Stage 1 or greater pelvic organ prolapse affecting one or more vaginal compartments&#xD;
             and no prior pelvic surgery&#xD;
&#xD;
          -  Stage 2 or greater pelvic organ prolapse affecting one or more vaginal compartments&#xD;
             and reconstructive surgery is scheduled&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active skin infection or ulceration within the vagina&#xD;
&#xD;
          -  Presence of a vaginal septum;&#xD;
&#xD;
          -  Active cancer of the colon, rectum wall, cervix, vaginal, uterus or bladder;&#xD;
&#xD;
          -  Ongoing radiation therapy for pelvic cancer;&#xD;
&#xD;
          -  Impacted stool&#xD;
&#xD;
          -  Recent (less than three months) pelvic surgery;&#xD;
&#xD;
          -  Significant pre-existing pelvic pain including levator ani syndrome, severe vaginismus&#xD;
             or vulvodynia;&#xD;
&#xD;
          -  Severe hemorrhoids&#xD;
&#xD;
          -  Surgically absent rectum or bladder&#xD;
&#xD;
          -  Significant circulatory or cardiac conditions that could cause excessive risk from the&#xD;
             examination as determined by attending physician&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Egorov, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Artann Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princeton Urogynecology</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Female Pelvic Medicine and Reconstructive Surgery</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sarvazyan A, Egorov V. Mechanical Imaging - a Technology for 3-D Visualization and Characterization of Soft Tissue Abnormalities. A Review. Curr Med Imaging Rev. 2012 Feb 1;8(1):64-73.</citation>
    <PMID>24058326</PMID>
  </results_reference>
  <results_reference>
    <citation>van Raalte H, Egorov V, Lucente V, Murphy M, Saiz C. 3D tactile imaging in early prolapse detection. International Continence Society 43rd Annual Meeting. Barcelona, Spain, 26-30 August, 2013.</citation>
  </results_reference>
  <results_reference>
    <citation>Egorov V, van Raalte H, Lucente V. Tactile imaging and tissue elasticity as a marker of pelvic floor conditions. International Urogynecological Association: 38th Annual Meeting, Dublin, Ireland, May 28-June 1, 2013.</citation>
  </results_reference>
  <results_reference>
    <citation>van Raalte H, Lucente V, Egorov V. Measuring outcome in urogynecological surgery by 3-D tactile imaging: First clinical experience. International Urogynecological Association: 38th Annual Meeting, Dublin, Ireland, May 28-June 1, 2013.</citation>
  </results_reference>
  <results_reference>
    <citation>van Raalte H, Egorov V, Lucente V. Tissue elasticity as a marker of pelvic floor conditions: Clinical results. Proceedings of the 11th International Tissue Elasticity Conference, Deauville, France, October 2-5, 2012: 46.</citation>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2011</study_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POP</keyword>
  <keyword>Pelvic Floor</keyword>
  <keyword>Pelvic Organ Prolapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

